Sheba Medical Centre

$100K raised for Sheba

Dr. Joe Schwarcz, director of the Office for Science and Society, McGill University, presented on The Chemistry of Wine and Its Many Benefits, at Canadian Friends of Sheba’s virtual event on May 2. (screenshot)

Canadian Friends of Sheba hosted Sheba Under the Stars on May 2, raising close to $100,000 for Israel’s Sheba Medical Centre. More than 100 guests attended the virtual evening featuring live entertainment, wine tasting and presentations on lifestyle choices from leading world experts.

Guests received a complimentary gift bag of wine and chocolates, and were treated to numerous performances from host Stacey Kay, Juno Award-winning singer/rapper and finalist on America’s Got Talent. The hour-long show also featured live wine tasting with Michael Avery, winemaker at Galil Mountain Winery, in Israel, as well as a presentation on The chemistry of Wine and Its Many Benefits, by Dr. Joe Schwarcz, director of the Office for Science and Society at McGill University.

Prof. Yitshak Kreiss, director general, Sheba Medical Centre, opened the event by highlighting Sheba’s global fight against the coronavirus through its recent support of missions to India, northern Italy, Cyprus and Uruguay, and called on the guests to be “inspired by Sheba’s vision to transform into the city of health.”

Presentations from “Sheba’s stars” included Redefining the Field of Lifestyle Medicine by Dr. Rani Polak, founding director of Sheba’s Centre of Lifestyle Medicine, and from Prof. Michal Schnaider Beeri, director of Sheba’s Joseph Sagol Neuroscience Centre, who shared tips on how wellness and lifestyle affects the brain.

To watch the full recording of the show, visit youtube.com/watch?v=QE2TRvm3G4Q.

Increased level of risk

Sheba Medical Centre recently published a study undertaken over three years by its department of obstetrics and gynecology in conjunction with Sheba Genetic Institute and the Genetics Institute in the Tel Aviv Sourasky Medical Centre, which found that women of Ashkenazi descent were twice as likely to have a baby born with Fragile X syndrome (FXS) compared to Jewish non-Ashkenazi women.

Nearly 600 female carriers of the FXS gene from various Jewish heritages participated in the study, which was published in the peer-reviewed publication Nature. Previously, it was known that only CGG repeats and AGG interruptions affect the risk for a child with FXS. This new research adds a third identifier, children of two Ashkenazi parents, allowing for better personalized genetic counselling for carriers who are trying to conceive.

FXS is the most common genetic cause of mental disability in an unborn child and causes intellectual disability, behavioural and learning challenges, and various physical characteristics. The prevalence of carriers in the Jewish population stands at about one in 150 women.

Dr. Noam Domniz of the IVF unit at Sheba Medical Centre said: “The new information from this study regarding the influence of ethnicity stresses the importance of providing more accurate and personally targeted genetic counseling to each woman, according to her personal level of risk. At Sheba, we aim to use this new approach to better evaluate each carrier’s risk level, empower them to make informed choices, leading to a clearer and safer road to motherhood.”

Israeli ventilation invention

Prof. Ori Efrati, left, and Dr. Michael Cohen. (photos from IMP)

With the arrival of the coronavirus vaccine, there has also been a spike in morbidity, clearly indicating that we’re not out of the woods yet. In fact, hospitals in Israel have warned that they are steadily approaching maximum capacity, as the numbers of severely ill COVID patients breaks all records.

When COVID-19 first erupted in March 2020, health authorities warned that a surfeit in severely ill coronavirus patients would overwhelm the system due, in large part, to a lack of ventilation machines – the standard of care for coronavirus patients whose condition deteriorates to pneumonia. In the ensuing months, Prof. Eyal Leshem, director of the Centre for Travel Medicine and Tropical Diseases at Sheba Medical Centre, explained that, in addition to the shortage of ventilators, one of the most pressing issues is the lack of highly trained intensive-care-unit staff to monitor patients attached to those devices.

An innovation by Yehonatan Medical addresses both of these issues.

Yehonatan Medical, in collaboration with Prof. Ori Efrati, director of the pediatric pulmonary unit at Sheba Medical Centre, devised a first-of-its-kind ventilation system that can treat multiple patients.

“Conventional ventilators, aside from being very costly, are limited in that they can only be used with one patient at a time,” explained Efrati. “Their capacity factor and programming functions were designed for single-patient use, and there is also the danger of cross-contamination.”

The new ventilation system resolves issues that corona ICU wards have been grappling with as the number of severely ill patients rises.

“We were able to use the relatively simple and inexpensive BipaP non-invasive ventilation machine as the basis for the advanced ventilation technology,” said Efrati. “Thanks to the high-power output and built-in disinfecting mechanism, the new system can safely treat three to five patients simultaneously.”

Moreover, a system that can treat multiple patients at one time necessitates fewer ICU-trained staff. Thanks to the remote interface, the medical team can monitor patients from a safe distance.

“This tremendous breakthrough is nothing less than a game-changer when it comes to caring for large numbers of corona patients,” Efrati added.

Dr. Michael Cohen, an engineer and scientist and the founder of Yehonatan Medical, said, “All in all, we’re talking about a system that delivers personalized care in a multi-user format.”

Additional features based on artificial-intelligence technology include the ability to have a hierarchy and classification of alerts; the ability for automatic parameter correction according to set criteria; respiratory rehabilitation for the patient by adjusting to changes in the patient responsiveness; and more. The streamlined, relatively low-cost system can be implemented in makeshift clinical settings, such as field hospitals, as well as in step-down units within the hospital, in the internal and other wards.

Yehonatan Medical is the medical department of Mofet Etzion, a company that for more than two decades has developed various security and military innovations for the Israel Defence Forces and foreign armies. Cohen has developed dozens of life-saving innovations, including in the area of cardiology, in collaboration with cardiologists and cardiothoracic surgeons from Israel, the United States and Canada.

“Some of the insights for the development of this revolutionary ventilation system were provided by cardiologists who helped us to devise the various accoutrements and sensors,” Cohen said, making specific mention of Dr. David Adams, professor and system chair of the cardiovascular surgery department at Mount Sinai Hospital in New York; Dr. David Tirone, chief of cardiac surgery at Toronto General Hospital; and Dr. Gideon Cohen, cardiothoracic surgeon at Sunnybrook Health Sciences Centre in Toronto. The development of the system itself took place in Israel, marking the first time that an invasive ventilation machine has been built in Israel.

The advanced ventilation technology is currently in advanced phase trials at the MSR Medical Simulation Centre at Sheba, where it is being tested on artificial lungs, and is expected to be ready for mass marketing in the coming months.

– Courtesy International Marketing and Promotion (IMP)

Breathing life into patients

Dr. Liran Levy, left, and Dr. Milton Saute. (photo from IMP)

Sheba Medical Centre in Israel and Canada’s Toronto General Hospital are collaborating to advance the field of lung transplantation in Israel and to enhance medical education in both countries.

In the last year, Sheba’s Institute of Pulmonary Medicine has established a new lung transplant program, headed jointly by Dr. Liran Levy – who, in 2019, completed four years of clinical, research and surgical training at Toronto General – together with surgeon Dr. Milton Saute, an expert in lung transplantation. According to Sheba’s head of pulmonary medicine, Dr. Amir Onn, collaboration with Toronto General will “put Sheba on the map of lung transplantation,” due, in large part, to revolutionary technology that can increase the number of donor lungs by almost 50%.

Toronto General is renowned for having performed the world’s first successful lung transplant, in 1983. They have since expanded their lung transplantation program, both clinically and in terms of research. One of the most groundbreaking discoveries was made in 2013 by Dr. Marcelo Cypel, a staff thoracic surgeon at Toronto General and director of their ECLS (extracorporeal life-support) program. This technique, said Cypel, “effected a change in paradigm for how we do lung transplants.”

photo - Dr. Amir Onn, left, and Dr. Marcelo Cypel — Dr. Amir Onn, left, and Dr. Marcelo Cypel. *(photo from IMP)*

The innovation, called ex vivo lung prefusion (EVLP), doubles the amount of time that the donor lungs can remain outside of the body. “Previously, donor lungs could be kept for only six to eight hours,” Cypel explained. “Patients had to uproot their lives to live near a transplant centre, and staff had to race against the clock to transfer the organ from the donor to the recipient, often forced to perform the complex surgery in the middle of the night.”

The valuable hours gained don’t just optimize the logistics of the operation, they actually allow for recovery of the organ itself.

“As a rule, over 80% of donor lungs are unsuitable for lung transplantation, due to poor functioning, infection, blood clots or injury,” said Cypel. By pumping a solution of oxygen, proteins and nutrients into the injured donor lungs, the EVLP system enables injured cells to heal themselves, or to be prepared for more sophisticated repair techniques. “The method doubled the number of lung transplants performed in Toronto in the last seven years,” he said.

With the help of Toronto General, Saute estimated that the EVLP program will become operational at Sheba by the middle of 2021. “We anticipate that [EVLP] will make a huge impact and significantly increase the pool of donors for lung transplantation in Israel, especially now, during COVID, with donors reduced by more than 50%,” he said.

According to Cypel, some of the reasons for the reduction in donor lungs during the pandemic include deaths that occur at home, due to reluctance of patients to seek hospital care, and the fewer car accidents (whose victims supply donor lungs) that occur while populations are in lockdown.

Collaboration will encompass clinical care, as well, including consultations regarding challenging patients, as well an exchange of trainees, in both directions. “We hope to send members of our team to Sheba to learn from their unique expertise,” Cypel said.

Onn added that COVID-19 has created new potential candidates for lung transplant. He is currently treating patients in Sheba’s designated post-COVID clinic who present with an unusual combination of symptoms – shortness of breath, chest pain and forgetfulness. Some, he said, have sustained irrevocable damage to the lungs.

A growing population of “COVID-19 survivors,” are being referred to the lung transplant centre. “We are in the process of identifying those who may be potential transplant cases,” said Levy.

Levy remarked that he is looking forward to working with his former colleagues and mentors from Toronto General. Looking back on his years spent in Canada with his wife and four children, he admitted that it was hard to leave. “The Jewish community made us feel very much at home, and we still miss Toronto,” he said. “But I think we have a very important mission here in Israel.”

When the teams from both hospitals met one year ago to discuss collaboration, Cypel and Saute were delighted to discover that they both hail from the same city in southern Brazil. “Although we didn’t meet in Brazil, Dr. Saute told me that he knew my grandparents quite well, and that was very emotional for me,” Cypel shared. Saute added that they both had the same mentor in thoracic surgery and, thus, “We have the same ideas.”

The scope of research and complexity of cases at Toronto General have made it a national and international source for discovery, education and patient care. Sheba Medical Centre, home to the ARC Innovation Centre, and where 25% of all clinical research in Israel takes place, has likewise distinguished itself in patient care, particularly in the era of COVID-19. Patients in both countries, and worldwide, can look forward to the fruits of this collaboration.

– Courtesy International Marketing and Promotion (IMP)

Dogs aiding recovery

Sheba is a trained physiotherapy dog. One of the patients he’s helping at Sheba Medical Centre is Nathaniel Felber, who suffered a head injury in a terror attack in December 2018. (photo from IMP)

Nathaniel Felber is an Israel Defence Forces soldier who suffered a critical head injury in a terror attack in December 2018. He has been slowly recovering, against all odds. After being in a coma for several months, he was moved to Sheba Medical Centre, where he’s been receiving intensive rehabilitation. After a brief setback following brain surgery last May, Felber has made remarkable progress, and a lot of the credit goes to Sheba – not only the hospital but its namesake, a trained physiotherapy dog.

“The dog relates to Nathaniel in a nonjudgmental way, happily accepting the food that Nathaniel offers or any other attention,” said Judi Felber, who has been at her son’s side almost constantly since the attack that upended their lives.

Prof. Israel Dudkiewicz, who heads Sheba’s orthopedic rehabilitation program, has noted a marked improvement in compliance, strength and endurance in patients like Felber, when performing physical therapy exercises with the dog.

“The dog takes attention away from the pain and difficulty of the exercise, enabling the patient to try to do more and to do it better,” explained Dudkiewicz. “I’ve watched patients who ordinarily wouldn’t be able to stand for just two or three minutes, but, when they pet the dog, they can be standing for 30 minutes and more without even realizing it.”

Felber builds strength and balance in his legs by standing and petting Sheba. He also throws a ball for the dog to retrieve, a game that repeatedly flexes his elbow, but without the tedium of the standard physio exercises for the same purpose. When brushing Sheba, Felber must exert enough pressure to run the brush through the dog’s fur, but not too much that would cause him pain.

The Felbers made aliyah from Silver Spring, Md., about 14 years ago, settling in Ra’anana with their three children and a dog. “Nathaniel loved our dog, and I think that interacting with Sheba the dog is very healing for him,” said his mother.

Dudkiewicz is delighted with Felber’s positive response to Sheba, as well as the responses of patients working with therapy dogs in general.

“We have seen dramatic improvement in patients performing physical therapy with dogs from both a physical and emotional perspective,” he said. “We aim to incorporate this as another treatment tool, such as hydrotherapy and other nonconventional therapies, for patients who can benefit from it.”

At just seven months old, Sheba is still a puppy, but his performance thus far points to a successful future. Dogs used in physical therapy must undergo a yearlong, rigorous training period. The staff must likewise be trained how to integrate the dog into their rehab programs. In the course of training, the dogs are tested periodically to see that they’re up to scratch. Dudkiewicz explained that different dogs are trained for different types of patients and their abilities. The cost of each dog, including training, is more than $30,000, meaning that its implementation in the department must be limited; however, Dudkiewicz said the results certainly justify the financial outlay.

“Neurorehabilitation is slower than anything else I’ve ever experienced,” said Judi Felber. “Nathaniel is not walking, or talking, or eating even independently – yet. But I try to focus on the positive: he’s responding to people, to us, his family. He’ll turn his head and give us his hand. He can nod yes and no and show us the number of fingers that we ask. We’ve still got a long way to go, but I’m hopeful.”

– Courtesy International Marketing and Promotion (IMP)

Inspiring students’ research

Students and staff of the recent Arrow Project on a tour of Sheba. In the centre is Prof. Eldad Katorza. Student Yair Jalmar is at the far right. (photo from IMP)

Sheba Medical Centre, Israel’s national hospital, enjoys a reputation for medical innovation, but many are unaware that it is also at the forefront of societal integration among various minority groups in Israel. In the past several years, Sheba has integrated hundreds of new Ethiopian olim (immigrants) into the hospital workforce, going as far as providing them with free classes to help them navigate Israeli bureaucracy and improve their language skills.

Recently, Prof. Eldad Katorza, senior physician at Sheba and director of the Arrow Project, decided to give youth from the Ethiopian community a head start by incorporating them into his pilot program.

The Arrow Project (Chetz in Hebrew, the initials of chokrim tze’irim, meaning “young researchers”) is an apprenticeship program for medical students, designed to pave their way into the world of research. Established in 2006, the initiative matches selected students with experienced researchers who serve as their mentors. During once- or twice-weekly meetings, the student-mentor teams work through every stage of medical research, from formulating the initial question, to collecting and analyzing data, to presenting the results at medical conferences.

This year, for the first time, each research duo also included a third tier: high school students from the Ethiopian community.

Katorza believes in the importance of encouraging students to pursue research, noting that, in med school, they do not receive sufficient exposure to research thinking or methodology.

“I believe that research makes a doctor more knowledgeable, more curious, more creative,” he said. “A doctor who engages in research is a much better doctor.”

Employing this premise, Katorza is planning to open several slots for nursing school students in the coming year’s program. “Nursing is also a field that stands to benefit greatly from adding researching to its ranks; it will raise the bar of nursing in Israel,” he said.

In the early stages of planning the pilot program for the Ethiopian high school students, it became evident to Katorza just how crucial, timely – and challenging – his initiative was. “I asked my son, then in 11th grade, to look around his own school in Givatayim for students from the Ethiopian community who might be suitable for the program,” said Katorza. “As it turned out, there wasn’t a single Ethiopian student in his school, nor in any of the good schools in the area.”

The reason can be traced to the socioeconomic realities in Israel today. Ethiopian Israelis have long experienced prejudice and being treated as second-class citizens. By and large, members of the Ethiopian community tend to dwell together in poorer neighbourhoods, where community services, schools included, are more limited. These conditions put Ethiopian teens at a disadvantage from the outset and, due to economic necessity, the youth are pushed to join the workforce at an early age, further perpetuating a cycle of poverty.

“Almost four decades have passed since the first wave of Ethiopian Aliyah,” said Katorza, “yet, judging from their rate of participation in academia, their level of affluence and other markers of social mobility, it appears that the government has failed to take the necessary steps to help them bridge the gaps and facilitate their successful absorption into mainstream Israeli society.”

Anxious to change this negative trend, Katorza decided to include outstanding students from the Ethiopian community in the Arrow Project. However, it wasn’t simple to locate high school students from the Ethiopian sector who met the criteria for participation in the program: high marks in the sciences, high motivation and interest, and living near enough to the Sheba campus to be able to easily attend the weekly meetings. Ultimately, Katorza was aided by an organization called Fidel (“Alphabet” in Amharic), which promotes the education and social integration of Ethiopian-Israeli youth. The Fidel staff welcomed this opportunity to incorporate Ethiopian students in Sheba’s research-mentoring platform, and provided 10 candidates, from which the top five were chosen.

According to Katorza, the pilot program was a resounding success and will be repeated in the coming year. “We found that, once they are freed from the limitations of their environment, the students manifested amazing capabilities,” he said. “We endeavoured to help build their self-confidence, empower them and teach them that they can do anything they put their mind to.”

Throughout the year, in addition to their full participation in research, the Ethiopian high schoolers were also exposed to the clinical activity at the hospital. “At the beginning of the year, the students didn’t have any specific plans for the future,” Katorza said. “Now, they are now seriously considering a medical career.”

One of those is Yair Jalmar, 17, from Beer Yaakov, who participated in a research project with pediatric cardiologist Dr. Shai Tejman. “This project helped me develop my interest in medicine and learn more about the advanced technologies and devices, as well as the various departments in the medical field,” he said.

In the 14 years since the project’s inception, the pool of participants, which in the beginning included only students from Tel Aviv University Sackler School of Medicine, has expanded to foreign exchange students from New York and London, as well as medical students from Ariel University, Bar-Ilan and others. Thus far, former participants in the Arrow Project have gone on to publish their findings in respected medical journals, and several have joined the team at Sheba.

– Courtesy International Marketing and Promotion (IMP)

Using apps and robots – coronavirus

One high-tech solution for patients possibly infected with the coronavirus is a robot that can enter the patient’s room and be controlled by medical staff from the outside. (photo from IMP)

Before the coronavirus arrived in Israel – there were two reported cases at press time – Sheba Medical Centre was preparing for it with different high-tech means: a telemedicine app that enables patients to receive care in the isolation, but comfort, of their own home; and robots that can treat in-hospital patients in order to minimize contact with staff.

Sheba’s Datos Health-In is a telemedicine app that enables patients to remain at home. In the event of an epidemic, with more patients than isolation rooms available, the app can be a viable tool for patients who are not severely ill. With the app, patients can enter vital signs and other information, which is directly accessed by their doctor. Patients can also establish contact with their physicians at any time of day or night.

The program was launched on Feb. 9 and tested on Israelis who had been in China and who, according to Health Ministry instructions, had to be in quarantine for 14 days, the incubation period of the virus. Doctors initialized contact with the patients twice a day.

photo - Sheba Medical Centre’s Dr. Galia Barkai — Sheba Medical Centre’s Dr. Galia Barkai *(photo from IMP)*

“This is one instance where telemedicine protects staff as well as other patients, by minimizing direct contact with those infected with the coronavirus,” explained Dr. Galia Barkai, head of telemedicine services at Sheba.

Another high-tech solution for patients possibly infected with the coronavirus is a robot that can enter the patient’s room and be controlled by medical staff from the outside. Designed by California-based virtual healthcare company Intouch Health, the robots are already in use in other departments, such as in the intensive care unit of pediatric cardiology, and the trauma unit.

“This technology is the perfect solution to provide care for in-patients infected with coronavirus, while protecting staff from contagion,” said Barkai.

Screening for the virus produces results in just a few hours but, with symptoms that are not very dramatic and that are reminiscent of the flu, including fever, cough and shortness of breath, Israel’s Health Ministry is only allowing those who have returned from China and a few other countries in the Far East to be tested.

– Courtesy International Marketing and Promotion (IMP)

High-tech medicine

A 1-year-old boy being treated with a novel gene therapy drug. “Usually, this type of injury with a hemophiliac patient would involve hours in the emergency room, with repeated doses of intravenous coagulation factors,” said Prof. Gili Kenet, director of the National Hemophilia Centre at Sheba Medical Centre. (photo from IMP)

From wearables that allow cardiac specialists at a hospital in Ramat Gan to monitor a patient’s cardiac performance thousands of miles away from home, to giving gravely ill patients a new lease on life with groundbreaking new therapies, Israeli medical innovators are almost literally thumbing their noses at the Angel of Death and changing the way we live.

According to start-up “ecosystem” sources, there are at least 6,000 active start-up companies operating in Israel. Within the realm of digital health, the number of active start-up companies engaged in this field has grown from 65 companies in 2005 to more than 400 in 2018. A significant number of these start-ups are being financially supported by global corporations such as Philips, GE Healthcare, Merck and IBM. Some of these companies have opened up offices close to start-up hubs in Haifa (near the Technion) and Metro Tel Aviv, the recognized “capital” of Israeli business and high-tech.

photo - This digital watch developed by the Sheba medical team and Datos Health is equipped with an app that contains a care path specially designed for each patient — This digital watch developed by the Sheba medical team and Datos Health is equipped with an app that contains a care path specially designed for each patient. *(photo from IMP)*

“Israel serves as a global incubator of innovative ideas for a variety of reasons,” said Dr. Eyal Zimlichman, deputy director general, chief medical officer and chief innovation officer at Sheba Medical Centre, which is located in Ramat Gan and is the largest facility of its kind in the Middle East. “First of all, it’s in our genes. Secondly, there is the military aspect, where we are taught to improvise when necessary in the field. These things allow us to be naturally innovative. This has trickled down into the medical field, where we are offering the highest level of medical care. I also believe unique innovations in medicine, that will impact the world for the next 100 years, will be developed in Israel.”

Prime examples of Sheba Medical Centre’s innovative efforts revolve around combating potentially fatal diseases such as cancer with immunotherapy, oncology’s new medical “magic bullet”; targeting hemophilia with a novel gene therapy drug; and creating an app for a wearable device used by people with serious heart and diabetes issues.

Immunotherapy is a treatment that uses our body’s own immune system to invade and destroy cancer. CAR-T (chimeric antigen receptor) and TIL (tumour-infiltrating lymphocytes) are not universal cancer cures at this stage. However, there are ongoing clinical trials being conducted for major pharmaceutical companies and America’s National Institutes of Health at Sheba Medical Centre’s oncology unit, where end-stage cancer patients are being treated with CAR-T, which specifically targets leukemia and lymphoma, and TIL, which zeroes in on melanoma and ovarian cancer patients.

Seventeen people with cancer were treated at Sheba during an initial CAR-T trial, after all of these patients had displayed zero improvement in the wake of traditional chemotherapy treatments and bone marrow transplants. Of the 17, 75% had a complete response to the CAR-T. One of those patients, an 8-year-old girl from Bnei Brak, was the first child to achieve complete remission from childhood leukemia. A Sheba centre oncologist said, “When we came to give her the CAR-T cells, she was very, very sick. She couldn’t even get out of bed. When we came back to visit her three weeks later, she was going back and forth on her rollerblades.”

A few weeks ago, a 1-year-old boy became the youngest patient in the world suffering from both severe hemophilia A and an unusual allergy to be treated with a gene therapy drug that only recently was approved for use in the United States. The new drug, developed by an American biopharmaceutical company, contained a “bispecific antibody” that was injected into the child at Sheba Medical Centre. According to clinical trial results published in The New England Journal of Medicine, the drug has shown a 90% reduction in bleeding in children and a 70% reduction in adults.

photo - Prof. Gili Kenet — Prof. Gili Kenet *(photo from IMP)*

“This is a new, exciting era with many novel options for improved care and even complete cure of patients with hemophilia,” said Prof. Gili Kenet, director of the National Hemophilia Centre at Sheba. “The child’s mother is so happy with the new treatment. The child had experienced a head trauma, but required no further therapy at all. Usually, this type of injury with a hemophiliac patient would involve hours in the emergency room, with repeated doses of intravenous coagulation factors. However, there were no complications, as his hemostasis (blood factors) was completely normal.”

Within the realm of what is known as IoT (internet of things), Prof. Robert Klempfner is blazing a trail of what he has dubbed IoMT (internet of medical things), where heart patients are able to engage in cardiac care and rehabilitation using wearables (for example, a high-tech watch), without having to return to the hospital for treatment.

“Today, the challenge for both heart doctors and cardiac care patients is what happens after a coronary event (heart attack), intervention or heart surgery,” said Klempfner. “What kind of regimen can be created for someone who might have had surgery at Sheba but lives and works in faraway places such as the United States or other countries? Within the new world of telemedicine and digital health, we have the technology to create rehab programs that are a win-win experience for both the hospital and the patient.

“We give cardiac care patients a watch,” he explained, “that is equipped with an app developed by the Sheba medical team and Datos Health [an Israeli start-up company]. The app contains a care path specially designed for each patient, containing rehab regimens, education material and secure communication with our patients. The medical centre receives data from wherever he/she is located when they are walking, exercising, doing other physical activities. Our technicians then analyze the info and provide ongoing feedback, assisted by smart algorithms provided by the innovative system.

“The program is also primed,” he said, “for patients who suffer from hypertension and diabetes that are now able to transmit all their measurements automatically to our system. This not only saves the patient time, by not having him/her return to the hospital, it saves the hospital time and bed space, so we are able to treat more patients. This ushers in a new era in digital healthcare.”

For more information on Sheba Medical Centre’s oncology unit, visit shebaonline.org.

Jumping gene research

Dr. Gideon Rechavi, who founded Sheba Cancer Research Centre, was in Vancouver in January for an international conference at which he presented new findings on “jumping genes.” (photo from Sheba Cancer Research Centre)

Dr. Gideon Rechavi, who founded Sheba Cancer Research Centre, in Ramat Gan, Israel, was in Vancouver in January for an international conference on DNA and RNA methylation.*

“I described a new work we just published, regarding ‘jumping genes,’” he told the Independent about his presentation at the conference. “Forty-five percent of our genome, part of what people used to call ‘junk DNA,’ is composed of genes that can jump from one place to another.”

As far as what this means for the functioning of a body, he explained, “When they jump, they can activate genes and they can also inactivate genes, and it’s a random process. Actually, when I was PhD student in ’82 at the Weizmann Institute, I found the first example of such an event in mammals.” And, he added, “We were also the first to show the role of such events in cancer.”

Rechavi explained, “In cancer, there is a set of genes called oncogenes, genes that usually are normal genes in our genome but, when they are over-activated or activated in the wrong cell or at the wrong time, they can push the cell to proliferate and can cause cancer.”

Now, he said, many years later, using advanced technologies based on whole genome sequencing, they have found that, “in a variety of neurodevelopmental disorders, such as autism and Rett syndrome and similar diseases, there is a basic gene defect in the family or in the affected child. However, the clinical presentation can differ even between identical twins. Nobody understands why the same genome and the same genetic background will result in such a difference, one patient will be affected by epilepsy, the other one by autism or mental retardation.

“The mechanism that we show is that, in the brain, there is, normally, a constant level of jumping of such genes and, probably, it’s essential for diversity of neurons and brain plasticity and activity.”

This is happening all the time in neuronal stem cells, he said. “During the differentiation of neuronal stem cells … there is a very precise time window of 48 hours when such transposition events can take place. And, probably, it’s essential, because you find it in mice, in monkeys and in humans. However, in all the diseases that we are studying, there is over-activation of the mechanism, so you have many more jumping events.”

We have neuronal stem cells dividing in the brain our whole life, said Rechavi. “In the past, we used to think that all of the neurons are created during pregnancy or soon after, but now, in the last 20 years or so, we know there are also adult neuronal stem cells. When you do gymnastics or when you take Prozac, there are more neuronal stem cells. And, in these neuronal stem cells, these transposable elements – jumping genes – are jumping and probably contribute to brain function.”

The process seems to be quite regulated, he said. “The mechanism we suggest, we call it the ‘lightning rod’ mechanism or hypothesis.”

He explained, “The majority of jumping events occur in sequences in the genome where integration will not cause harm. So, in a normal level of jumping, we expect it will be beneficial, and the chance for damage is low. Although, if, in a variety of diseases, there is uncontrolled activation of this mechanism, so there are many more jumps, then it can saturate the lightning rod safeguard mechanism and then affect genes that are relevant to neuronal diseases, and we have a lot of examples where such things happened.”

To study this, said Rechavi, they sequenced the genomes of 100 samples, which included normal, diseased and control brain samples. “We were able to show that there is a particular normal level of transposition … and, then, over-activation, with many more transposition events, in the brains of disease-affected children.”

From these results, he said, we know that “the genes affected by such insertions from these transpositions, you see that many of them are relevant to neuronal functioning, neural development and a variety of neuronal disorders, such as autism and schizophrenia.”

By understanding the biochemical mechanism in these patients, what activates the jumping, “then you can intervene,” said Rechavi. For example, perhaps a drug could be developed that would decrease the level of transposition.

“This is the next step,” he said. “Now, we have several patients where we know the gene defect involved in the syndrome and, therefore, is involved in the enhanced transposition, so now we have to find a way to shut it off, to lower the activity.”

Rechavi said his lab is researching these jumping genes and their effects in both cancer and neuronal disorders, and that they are currently looking for funding to study the involvement of such genes in Alzheimer’s and in aging.

The purpose of the jumping genes is not certain. “What people suggest,” said Rechavi, “is that it has to do with diversity.” Recalling that it is a random process, he explained, “So, instead of having all the neurons in a particular part of the brain being identical, now you have diversity and probably the diversity increases the efficiency of the brain circuits, etc. It can also be relevant to plasticity. We know that specific brain regions can take over following damage or following a kind of environmental influence and change the activity and perform new activities. So, maybe the ability to create diversity in the brain is an advantage.

“A similar model has to do with the immune system,” he added. “With the immune system, we know that there are genetic mechanisms that increase diversity and, then, the cells of the immune system of an individual can respond to any virus and any bacteria.”

The main focus of his lab at Sheba Medical Centre, he said, is to find new genetic and epigenetic mechanisms, “and then to ask, what is their relevance to normal physiology and what’s their relevance to diseases. That’s how this story that started with cancer research turned out to be very relevant to neuronal disorders and psychiatric disorders.”

Rechavi said the phenomenon of jumping genes, or transposable elements, was first identified by American scientist Barbara McClintock (1902-1992) in experiments with maize. (She won the Nobel Prize in 1983 for this and other contributions to the study of genetics.) “She found it in maize,” he said. “We found it in mammals.”

Conferences like the one Rechavi was attending in Vancouver when he spoke to the Independent by phone Jan. 23 from his room at the Fairmont Hotel Vancouver, where the conference was being held, are useful for several reasons.

“Some people, after my talk, came and they wanted to collaborate, they want to learn the methodologies. Some people suggested samples we could analyze…. This is the basis for scientific collaboration, the main reason to do scientific meetings. You can read everything on the internet,” he said, “but when you discuss with people the findings and you drink coffee together and discuss the details, you can get new information, new non-published information, and also collaborations and friendships.”

Sheba Medical Centre doesn’t have many partnerships with Canadian institutions, said Rechavi. The centre’s main collaboration in Canada, he said, is with Toronto’s Hospital for Sick Children, especially in the field of brain tumours, because one of Rechavi’s former trainees, Dr. Uri Tabori, went to SickKids to study such tumours and stayed there.

Before obtaining his PhD at the Weizmann Institute of Science, in Rehovot, Rechavi earned his doctor of medicine at Tel Aviv University’s Sackler School of Medicine. He is a professor of hematology at Sackler School and heads the Cancer Research Centre at Sheba Medical Centre, the largest hospital in Israel, which serves as a university teaching hospital (affiliated with Sackler) and as a tertiary referral centre. He has published more than 450 scientific papers.

In addition to treating some 1.5 million patients annually, Sheba Medical Centre has 75 laboratories and more than 2,000 ongoing clinical trials; 30% of Israeli medical research is performed at Sheba, which files, on average, 15 biomedical patent applications per year.

In October 2017, Sheba Medical Centre inaugurated the Wohl Institute for Translational Medicine. The idea, said Rechavi, is to take the “findings emerging from basic research and try to translate it into taking care of patients; to better diagnose, to [develop] better treatments.”

* Methylation, explained Dr. Gideon Rechavi, “is the addition of a chemical group known as methyl on the four basic letters of the genetic material (DNA and RNA) to generate a new expanded ‘alphabet.’”

NCSY at Sheba centre

Dr. Amit Segev gets his heart checked out by one of the participants in NCSY Canada’s Jewish Journeys summer program. Segev gave all the teens a stethoscope to commemorate their visit to Sheba Medical Centre. (photo from SMC)

More than 30 teenage participants from NCSY Canada’s Jewish Journeys summer program were recently treated to a VIP tour of Sheba Medical Centre’s Olga and Lev Leviev Heart Centre.

Dr. Amit Segev, director of Sheba Medical Centre’s cardiac division, showed the group a short presentation of how the heart can malfunction and what doctors can do to save patient’s lives in such instances. As there is nothing like a dose of reality to enhance the experience, Segev showed the teens a live view of a medical procedure being performed on a patient suffering from a heart malfunction.

As a token of appreciation for their visit – and perhaps spur their interest in a future medical career – Segev gave each participant a Sheba Medical Centre stethoscope.